Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




An Omics Approach for Predicting Mutations in Protein-Metal Binding Sites

By LabMedica International staff writers
Posted on 06 Jan 2020
A deep learning approach was developed that was able to predict how mutations in the metal-binding sites of metalloproteins were related to various diseases.

Metalloproteins play important roles in many biological processes. More...
Mutations at the metal-binding sites may functionally disrupt metalloproteins, initiating severe diseases; however, there has not been an effective approach for predicting such mutations.

In this regard, investigators at the University of Hong Kong (China) developed an “omics”-based deep learning approach to predict disease-associated mutations of the metal-binding sites in a protein. Omics (such fields as genomics, proteomics, etc.) aims at the collective characterization and quantification of pools of biological molecules that translate into the structure, function, and dynamics of an organism or organisms.

The investigators began by integrating omics data from different databases to build a comprehensive computer training dataset. Statistical analysis of the collected data revealed that various metals had different disease associations. A mutation in zinc-binding sites had a major role in breast, liver, kidney, immune system, and prostate diseases. By contrast, mutations in calcium- and magnesium-binding sites were associated with muscular and immune system diseases, respectively. Mutations in iron-binding sites were associated with metabolic diseases. In addition, mutations of manganese- and copper-binding sites were associated with cardiovascular diseases, and copper-binding site mutations were also associated with nervous system diseases.

The investigators generated energy-based affinity grid maps and physiochemical features of the metal-binding pockets (obtained from different databases as spatial and sequential features) and subsequently incorporated these features into a multichannel convolutional neural network. After training the model, the multichannel convolutional neural network successfully predicted disease-associated mutations that occurred at the first and second coordination spheres of zinc-binding sites with an area under the curve of 0.90 and an accuracy of 0.82.

Senior author Dr. Hongzhe Sun, professor of bioinorganic chemistry at the University of Honk Kong, said, "Machine learning and AI play important roles in the current biological and chemical science. In my group we worked on metals in biology and medicine using integrative omics approach including metallomics and metalloproteomics, and we already produced a large amount of valuable data using in vivo/vitro experiments. We now develop an artificial intelligence approach based on deep learning to turn these raw data to valuable knowledge, leading to uncover secrets behind the diseases and to fight with them. I believe this novel deep learning approach can be used in other projects, which is undergoing in our laboratory."

The mettaloprotein binding site mutations paper was published in the December 9, 2019, online edition of the journal Nature Machine Intelligence.

Related Links:
University of Hong Kong


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.